CD8A and neoplasm: TIGIT competitively binds CD155/CD112 on the APC/tumor cells which exerts immunosuppressive effects on CD8+T cells that are highly expressed the multiple IRs, eventually resulting in the formation of exhausted T cells that have lost their tumor-killing effect [31,42,43].